DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
IQM-PC332, a Novel DREAM Ligand with Antinociceptive Effect on Peripheral Nerve Injury-Induced Pain
Neuropathic pain is a form of chronic pain arising from damage of the neural cells that sense,
transmit or process sensory information. Given its growing prevalence and common refractoriness
to conventional analgesics, the development of new drugs with pain relief effects constitutes a
prominent clinical need. In this respect, drugs that reduce activity of sensory neurons by modulating
ion channels hold the promise to become effective analgesics. Here, we evaluated the mechanical
antinociceptive effect of IQM-PC332, a novel ligand of the multifunctional protein downstream
regulatory element antagonist modulator (DREAM) in rats subjected to chronic constriction injury of
the sciatic nerve as a model of neuropathic pain. IQM-PC332 administered by intraplantar ( 0.01–10 μg)
or intraperitoneal (0.02–1 μg/kg) injection reduced mechanical sensitivity by ≈100% of the maximum
possible effect, with ED50 of 0.27 ± 0.05 μg and 0.09 ± 0.01 μg/kg, respectively. Perforated-patch
whole-cell recordings in isolated dorsal root ganglion (DRG) neurons showed that IQM-PC332
(1 and 10 μM) reduced ionic currents through voltage-gated K+ channels responsible for A-type
potassium currents, low, T-type, and high voltage-activated Ca2+ channels, and transient receptor
potential vanilloid-1 (TRPV1) channels. Furthermore, IQM-PC332 (1 μM) reduced electrically evoked
action potentials in DRG neurons from neuropathic animals. It is suggested that by modulating
multiple DREAM–ion channel signaling complexes, IQM-PC332 may serve a lead compound of novel
multimodal analgesics., This research was funded by Universidad Complutense de Madrid grants: PR75/18-
21593 and FEI20/35 (to A.R.A.), and Ministerio de Ciencia e Innovación, AEI-FEDER, EU grants:
SAF2016-75021-R and PID2019-104366RB-C21 (to C.V.), PID2019-109155RB-I00 (to A.R.A.), PID2019-
104366RB-C22 (to M.G.-R), Instituto de Salud Carlos III CIBERCV program: CB/11/00222 (to C.V.);
Consejo Superior de Investigaciones Científicas grants: PIE202180E073 (to M.G.-R.), PIE201820E104
and 2019AEP148 (to C.V.). P.G.S. was funded with a fellowship from the Ministerio de Ciencia e
Innovación (FPU17/02731)., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-104366RB-C21
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-109155RB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-104366RB-C22